hcc with advanced cirrhosis 伴重度肝硬化肝细胞癌
Summary Ongoing trials are evaluating the role of other targeted therapies in patients with advanced HCC.
正在进行的一些试验是评估其它靶向治疗对于进展期肝癌的病人的作用。
The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.
目前还没有2期或3期试验对索拉非尼与多柔比星联用治疗晚期HCC患者进行评价。
For those patients with advanced HCC, who have had surgical resection, with the surgery impact the safety and efficacy of sorafenib?
对于已进行了手术的晚期肝癌患者，手术会影响索拉非尼的安全性和疗效吗？
应用推荐